No Data
Express News | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
Express News | Organon Completes Acquisition of Dermavant, Including Innovative Dermatologic Therapy, Vtama® (Tapinarof) Cream, 1%
Express News | Dermavant Presents Final Data From ADORING 3 LTE Study On VTAMA Cream, 1% At 2024 Fall Clinical Dermatology Conference; 51.9% Achieved Complete Disease Clearance And Remained Treatment-Free For ~80 Days; FDA PDUFA Action Date Expected Q4 2024
Editas, Roivant's Genevant to Develop Gene Editing Therapies
Leerink Partners Maintains Roivant Sciences(ROIV.US) With Buy Rating
Price Over Earnings Overview: Roivant Sciences